Publications

Morrow WP, Milligan NS, Ohgami RS, Young KH, Wang B, Vega F, Marques-Piubelli ML, Feldman AL, Slack GW, Savage KJ, Zhao X, Rubenstein JL, Hsi ED. Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. Journal of hematopathology. 2024. PMID: 39549220


Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, Lai C, Wainberg ZA. A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies. European journal of cancer (Oxford, England : 1990). 2024. PMID: 39793445


Chen LY, Thibaud S, Bodnar S, Chari A, Richter J, Cho HJ, Sanchez LJ, Rodriguez C, Rossi AC, Richard S, Parekh S, Jagannath S. MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients. Blood advances. 2024. PMID: 39546749


Yarava A, Marshall C, Reichert DE, Ye A, Khanal P, Robbins SH, Sachais BS, Oh D, Metcalf RA, Conry-Cantilena K, King K, Reyes M, Adamski J, Marques MB, Tran MH, Allen ES, Pach D, Blumberg N, Hobbs R, Nash T, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Rausch W, Oei K, Abinante M, Forthal DN, Zand MS, Kassaye SG, Cachay ER, Gebo KA, Shoham S, Casadevall A, McBee NA, Amirault D, Wang Y, Hopkins E, Shade DM, Layendecker O, Klein SL, Park HS, Lee JS, Caturegli P, Raval JS, Cruser D, Ziman AF, Gerber J, Gniadek TJ, Bloch EM, Tobian AAR, Hanley DF, Sullivan DJ, Lane K, CSSC (COVID 19 Serologic Studies Consortium) group. Creating a plasma coordination center to support COVID-19 outpatient trials across a national network of hospital blood banks. Journal of clinical and translational science. 2024. PMID: 39655012


Geng H, Mo SS, Chen L, Ballapuram A, Tsang M, Lu M, Rauschecker AM, Wen KW, Devine WP, Solomon DA, Rubenstein JL. Identification of Genomic Biomarkers of Disease Progression and Survival in Primary CNS Lymphoma. Blood advances. 2024. PMID: 39536287


Luck C, Jacobs KA, Okimoto RA. The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein. Cancer Research Communications. 2024. PMID: 39530749


Mennillo E, Lotstein ML, Lee G, Johri V, Ekstrand C, Tsui J, Hou J, Leet DE, He JY, Mahadevan U, Eckalbar W, Oh DY, Fragiadakis GK, Kattah MG, Combes AJ. Single-cell spatial transcriptomics of fixed, paraffin-embedded biopsies reveals colitis-associated cell networks. bioRxiv : the preprint server for biology. 2024. PMID: 39605355


Kim J, Munster PN. Estrogens and breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. PMID: 39522613


Bazhenova L, Kim DW, Cho BC, Goel S, Heist R, Werner TL, Eaton KD, Wang JS, Pant S, Adkins DR, Blakely CM, Yan X, Neuteboom S, Christensen JG, Chao R, Bauer T. Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. Future oncology (London, England). 2024. PMID: 39513224


Weinfurtner K, Tischfield D, McClung G, Crainic J, Gordan J, Jiao J, Furth EE, Li W, Supan ET, Nadolski GJ, Hunt SJ, Kaplan DE, Gade TPF. Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts. JHEP reports : innovation in hepatology. 2024. PMID: 40028346


Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO precision oncology. 2024. PMID: 39509670


Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO precision oncology. 2024. PMID: 39509670


Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO precision oncology. 2024. PMID: 39509670


Sarwahi V, Rahman E, Eigo K, Galina J, Hasan S, Ko A, Lo Y, Amaral T, Djukic A, Santiago M, Schneider J. Perioperative Considerations in Patients with Rett Syndrome as Compared to Those with Cerebral Palsy. Spine. 2024. PMID: 39505565


Jun Ma, Michael P Randall, Ming Lu, Lingjing Chen, Huimin Geng, Aishwarya Kumar, Saloni Malla, Mark Noviski, Ryan Rountree, James L. Rubenstein. BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models. Blood. 2024. PMID:


Michael P Randall, Huimin Geng, Lingjing Chen, Aishwarya Ballapuram, Chitoh Yung, Ming Lu, Gregory Chin, Michael Mish, Jamie Bates, James L. Rubenstein. Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma. Blood. 2024. PMID:


Alvaro J Alencar, Olivia Bobek, Neha Mehta-Shah, Narendranath Epperla, Christine Lu-Emerson, Sarah C. Rutherford, Adam J. Olszewski, Thomas Ollila, Samuel Singer, Travis Dockter, Susan M. Geyer, Lori Rosenstein, Macarena De La Fuente, Eric D. Hsi, Shira N. Dinner, James L. Rubenstein, Nancy L. Bartlett, John P. Leonard. Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). Blood. 2024. PMID:


Kelly Schoenbeck, Isabelle Vu, Albert Lee, Mansa Devaki, Insiyah Merchant, Faaiz Ibrahim, Anand Dhruva, Catherine C. Smith, Neil P. Shah, Chloe Atreya. Living with CML: A Qualitative Analysis. Blood. 2024. PMID:


Matthew F Jones, Cheryl A C Peretz, Vanessa E. Kennedy, Elaine Tran, Andrew Koh, Andriana Kotini, Malgorzata Olszewska, Eirini Papapetrou, Catherine C. Smith. AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance. Blood. 2024. PMID: